Olympus (7733) AI Stock Analysis

• Market Cap: ¥2.18T
• Dividend Yield: 1.03%
• Average Volume (3M): 3.66M
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.90
• Revenue Growth: 6.53%
• EPS Growth: -46.94%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 29.73
• Shares Outstanding: 1,139,116,300
• 10 Day Avg. Volume: 4,056,480
• 30 Day Avg. Volume: 3,657,346
• PEG Ratio: 0.80
• Price to Book (P/B): 4.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 105.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,340.39
• Price Target Upside: 22.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 77 Outperform
• Price Target: ¥2,203.00 ▲(15.07%Upside)

Olympus's strong financial performance, characterized by robust revenue and cash flow growth, is the most significant factor contributing to the stock's score. Technical indicators show positive momentum, though nearing overbought levels which should be monitored. The valuation appears fair, balancing potential growth with income from dividends.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation, headquartered in Japan, is a leading manufacturer specializing in precision machinery and instruments. The company operates in several sectors including medical, scientific solutions, and imaging. Its core products and services include medical equipment such as endoscopes, microscopes for scientific research, and a range of cameras and audio products. Olympus is renowned for its innovation in optical and digital technology, serving a diverse clientele across healthcare, life sciences, and consumer markets.

How the Company Makes Money

Olympus primarily generates revenue through its Medical Systems business, which accounts for the largest portion of its income. This segment includes the manufacture and sale of endoscopic, therapeutic, and surgical devices used in minimally invasive procedures. The company's Scientific Solutions division also contributes significantly to its earnings by providing microscopes and industrial measurement and imaging instruments. Additionally, Olympus earns money through its Imaging division, which offers digital cameras and audio products, although this segment has seen a decline in recent years. Key revenue streams are bolstered by ongoing research and development, strategic partnerships with healthcare institutions, and a strong global distribution network.

Olympus Financial Statement Overview

Summary

Olympus demonstrates strong financial health with robust revenue growth and efficient cost management, as evidenced by a strong gross profit margin above 67%. The balance sheet is stable with improving equity and debt management, though fluctuations in net income and free cash flow indicate some volatility.

Income Statement

Olympus has demonstrated a strong revenue growth rate, with consistent annual increases culminating in a 6.52% growth in 2025. The company's gross profit margin remains robust, consistently above 67% in recent years, which indicates efficient cost management. The net profit margin improved significantly in 2025 compared to previous years. EBIT and EBITDA margins are healthy, showcasing strong operational performance. However, fluctuations in net income, particularly the drop in 2024, highlight some volatility in profitability.

Balance Sheet

The balance sheet shows a solid equity position with an improving equity ratio, reaching 52.45% in 2025, indicating financial stability. The debt-to-equity ratio decreased, reflecting effective debt management. Return on equity has been strong, though it experienced fluctuations due to varying net income levels. The company's leverage has been reduced over recent years, enhancing financial flexibility.

Cash Flow

Olympus has shown impressive growth in free cash flow, particularly in 2025, following a challenging 2024. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to profits. The company has maintained a positive free cash flow, demonstrating strong cash management. However, the fluctuations in free cash flow highlight potential volatility in cash generation.

Breakdown
Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
997.33B	936.21B	881.92B	868.87B	730.54B
	Gross Profit
683.70B	625.12B	596.85B	571.70B	459.53B
	EBIT
185.71B	43.60B	186.61B	153.90B	81.98B
	EBITDA
231.90B	112.10B	238.82B	233.16B	160.81B
	Net Income Common Stockholders
117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
252.53B	340.93B	180.69B	312.84B	227.75B
	Total Assets
1.43T	1.53T	1.51T	1.36T	1.18T
	Total Debt
229.10B	299.62B	340.06B	386.13B	355.26B
	Net Debt
-23.43B	-41.32B	170.73B	83.56B	137.79B
	Total Liabilities
681.09B	777.03B	867.07B	846.64B	785.54B
	Stockholders Equity
751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow		Free Cash Flow
144.46B	-22.26B	27.87B	107.96B	64.89B
	Operating Cash Flow
190.46B	42.37B	98.49B	169.73B	124.12B
	Investing Cash Flow
-65.47B	359.99B	-58.41B	-71.02B	-118.92B
	Financing Cash Flow
-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1914.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Neutral. The current price of 1914.5 is above the 20-day moving average (MA) of 1871.92, above the 50-day MA of 1859.54, and below the 200-day MA of 2264.20, indicating a neutral trend. The MACD of 13.01 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 78.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7733	77 Outperform	¥2.18T	18.81	15.47%	1.03%	6.53%	-46.94%
7741	70 Outperform	¥5.86T	29.46	20.56%	1.34%	13.56%	12.78%
4543	70 Outperform	$3.92T	33.55	8.56%	0.95%	12.40%	10.51%
7747	69 Neutral	$640.63B	60.83	7.09%	0.66%	17.38%	-30.54%
8086	64 Neutral	€210.72B	41.21	2.07%	2.03%	9.85%	-53.97%
6869	63 Neutral	$1.51T	28.14	11.84%	1.34%	10.21%	8.55%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%

Olympus Corporate Events

Olympus Reports FY2025 Financial Results Amid Business Reorganization

Olympus has reported its financial results for FY2025, highlighting a reorganization of its business segments and the divestiture of its orthopedic business. The company recorded a gain from the sale of its Evident operation in FY2024 Q1 and anticipates further changes as it transitions its focus towards gastrointestinal and surgical solutions, impacting its financial reporting and market strategy.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Share Repurchase and Cancellation Plan

Olympus Corporation announced a strategic move to repurchase up to 36 million of its common shares, representing 3.19% of its outstanding shares, with a maximum expenditure of 50 billion yen. This decision aims to enhance shareholder returns and improve capital efficiency, with the repurchase scheduled between July and October 2025, followed by the cancellation of the repurchased shares in November 2025, excluding those allocated for stock compensation.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports Strong Operating Profit Amidst Strategic Restructuring

Olympus Corporation reported a significant increase in operating profit for the fiscal year ended March 31, 2025, despite a decline in total comprehensive income. The company has classified its Orthopedic Business as a discontinued operation, impacting the financial results. The forecast for the next fiscal year indicates a slight increase in revenue, but a decrease in operating profit and profit attributable to owners. The company also announced changes in its consolidation scope, including the addition of Olympus Corporation Chile and the exclusion of two other companies.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Leadership Changes to Drive Growth

Olympus Corporation announced significant leadership changes, appointing Bob White as the new Representative Executive Officer, President, and CEO, effective June 1, 2025. This decision is part of a strategic succession process aimed at driving further transformation and growth in the global MedTech sector. The appointment reflects the company’s commitment to leveraging White’s extensive experience in the medical device industry to enhance its market position and create value for stakeholders.

Olympus Corporation’s Commitment to Governance and Diversity

Olympus Corporation has released a corporate governance report detailing its adherence to the Corporate Governance Code and its strategic focus on diversity, equity, and inclusion (DEI). The company has significantly reduced its policy shareholdings and is actively promoting diversity through various initiatives, including supporting women and people with disabilities in the workplace. These efforts are part of Olympus’s broader strategy to enhance its corporate governance and ensure a diverse and inclusive work environment, which is crucial for its long-term success and stakeholder trust.

Olympus Proposes New Board Member to Enhance Global Strategy

Olympus Corporation has announced a proposed change to its Board of Directors, with Hiroshi Ishino being nominated as a new Outside Director, replacing Sumitaka Fujita. Ishino’s extensive experience in global business expansion and management is expected to contribute to Olympus’s sustainable growth and corporate value enhancement.